Product
TG-C
Aliases
TG-C High Dose, TG-C Low Dose, TG-C Mid Dose, TissueGene-C
4 clinical trials
2 indications
Indication
degenerative disc diseaseIndication
OsteoarthritisClinical trial
A Phase I, Double-blind, Randomized, Sham-controlled, Dose-response, Study Evaluating the Safety and Tolerability of TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease at 6 and 12 MonthsStatus: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the KneeStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the KneeStatus: Active (not recruiting), Estimated PCD: 2024-03-06
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects With Symptomatic Early Hip OsteoarthritisStatus: Not yet recruiting, Estimated PCD: 2025-10-01